RE:RE:Blue Sky scenario for Vascepa alone $75 per shareAMRN has mid-70's gross margin on its sales and I believe they are selling to HLS at cost +? which I assume could lead to HLS having gross margins about 55% (anyone?) so, when they ever do achieve the $150MM annual sales, that is $83MM gross. Cannot see HLS needing the same amount of sales/marketing staff for the 50K or so doctors and cardio/endocrino consutants and every $1.2MM in commissions at 2% of gross means possibly 21new staff, so even $10MM gives 160 or so new staff. $83MM less $10MM is over $2.00/sh before royalties and other related expenses. HSL is committed I believe to possibly another $45MM in license fees and other royalties to AMRN over period to 2023. Can see the $30 tp v. achievable but as with other new drugs in canada there needs to be caution not to expect too much too soon. Comments?